Copyright
©The Author(s) 2025.
World J Clin Cases. Feb 6, 2025; 13(4): 95803
Published online Feb 6, 2025. doi: 10.12998/wjcc.v13.i4.95803
Published online Feb 6, 2025. doi: 10.12998/wjcc.v13.i4.95803
Total (n = 6094) | Without ischemic stroke (n = 5951) | With ischemic stroke (n = 143) | P value | |
Variables | ||||
Age (years) | 62.32 ± 13.00 | 62.20 ± 13.04 | 66.97 ± 10.60 | < 0.001 |
Gender-female | 3292 (54.0) | 3221 (54.1) | 71 (49.7) | 0.329 |
Current smoking | 1606 (26.4) | 1558 (26.2) | 48 (33.6) | 0.060 |
Current drinking | 796 (13.1) | 780 (13.1) | 16 (11.2) | 0.583 |
Body mass index (kg/m2) | 25.07 ± 4.17 | 25.06 ± 4.18 | 25.46 ± 3.69 | 0.248 |
Physical activity | 0.065 | |||
Never | 2547 (41.8) | 2474 (41.6) | 73 (51.0) | |
Occasionally | 755 (12.4) | 738 (12.4) | 17 (11.9) | |
Often | 2790 (45.8) | 2737 (46.0) | 53 (37.1) | |
Diabetes | 1198 (19.7) | 1165 (19.6) | 33 (23.1) | 0.353 |
Coronary heart disease | 85 (1.4) | 83 (1.4) | 2 (1.4) | 1.000 |
Antihypertensive drugs | 3448 (56.6) | 3353 (56.3) | 95 (66.4) | 0.020 |
Hypoglycemic agents | 1031 (16.9) | 1004 (16.9) | 27 (18.9) | 0.603 |
Lipid-lowering drugs | 1009 (16.6) | 987 (16.6) | 22 (15.4) | 0.789 |
Total cholesterol (mg/dL) | 214.47 ± 45.95 | 214.29 ± 45.82 | 222.05 ± 50.83 | 0.046 |
Triglyceride (mg/dL) | 164.98 ± 149.66 | 164.88 ± 150.17 | 169.02 ± 127.06 | 0.744 |
Low-density lipoprotein cholesterol (mg/dL) | 119.85 ± 32.31 | 119.71 ± 32.13 | 125.75 ± 38.87 | 0.027 |
High-density lipoprotein cholesterol (mg/dL) | 48.59 ± 14.12 | 48.64 ± 14.19 | 46.45 ± 10.75 | 0.067 |
Fasting blood glucose (mmoL/L) | 5.13 ± 1.57 | 5.12 ± 1.55 | 5.42 ± 2.05 | 0.023 |
Systolic blood pressure (mmHg) | 130.47 ± 15.65 | 130.34 ± 15.64 | 135.72 ± 15.39 | < 0.001 |
Diastolic blood pressure (mmHg) | 80.52 ± 9.99 | 80.49 ± 9.98 | 81.82 ± 10.18 | 0.117 |
Estimated glomerular filtration rate (mL/minute/1.73 m2) | 95.74 ± 39.90 | 95.79 ± 39.33 | 93.92 ± 58.98 | 0.581 |
Normal was transformed into normal group | Abnormal was transformed into normal group | Normal was transformed into abnormal group | Abnormal was transformed into abnormal group | P value | |
Variables | 1786 | 979 | 883 | 2446 | |
Age (years) | 63.65 ± 13.54 | 61.23 ± 13.46 | 63.13 ± 11.71 | 61.48 ± 12.76 | < 0.001 |
Gender-female | 958 (53.6) | 455 (46.5) | 555 (62.9) | 1324 (54.1) | < 0.001 |
Current smoking | 461 (25.8) | 277 (28.3) | 202 (22.9) | 666 (27.3) | 0.034 |
Current drinking | 225 (12.6) | 149 (15.2) | 87 (9.9) | 335 (13.7) | 0.004 |
Body mass index (kg/m2) | 23.69 ± 3.82 | 25.39 ± 3.65 | 24.98 ± 5.31 | 25.98 ± 3.86 | < 0.001 |
Physical activity | 0.006 | ||||
Never | 781 (43.8) | 395 (40.3) | 351 (39.8) | 1020 (41.7) | |
Occasionally | 219 (12.3) | 148 (15.1) | 89 (10.1) | 299 (12.2) | |
Often | 785 (44.0) | 436 (44.5) | 443 (50.2) | 1126 (46.1) | |
Diabetes | 238 (13.4) | 211 (21.6) | 148 (16.8) | 601 (24.6) | < 0.001 |
Coronary heart disease | 17 (1.0) | 14 (1.4) | 10 (1.1) | 44 (1.8) | 0.116 |
Antihypertensive drugs | 786 (44.0) | 562 (57.4) | 533 (60.4) | 1567 (64.1) | < 0.001 |
Hypoglycemic agents | 202 (11.3) | 200 (20.4) | 116 (13.1) | 513 (21.0) | < 0.001 |
Lipid-lowering drugs | 0 (0.0) | 225 (23.0) | 0 (0.0) | 784 (32.1) | < 0.001 |
Total cholesterol (mg/dL) | 189.05 ± 27.72 | 190.17 ± 48.24 | 202.90 ± 27.18 | 215.02 ± 54.14 | < 0.001 |
Triglyceride (mg/dL) | 101.13 ± 36.47 | 163.79 ± 122.33 | 120.26 ± 38.08 | 228.21 ± 201.58 | < 0.001 |
Low-density lipoprotein cholesterol (mg/dL) | 93.02 ± 20.64 | 94.92 ± 27.47 | 101.27 ± 21.15 | 103.35 ± 33.74 | < 0.001 |
High-density lipoprotein cholesterol (mg/dL) | 52.66 ± 9.81 | 43.03 ± 11.78 | 51.82 ± 11.61 | 46.68 ± 17.05 | < 0.001 |
Fasting blood glucose (mmol/L) | 4.93 ± 1.38 | 5.14 ± 1.46 | 4.95 ± 1.22 | 5.33 ± 1.80 | < 0.001 |
Systolic blood pressure (mmHg) | 128.64 ± 15.78 | 130.32 ± 15.42 | 131.31 ± 15.99 | 131.55 ± 15.41 | < 0.001 |
Diastolic blood pressure (mmHg) | 79.41 ± 10.17 | 80.94 ± 9.82 | 80.13 ± 10.04 | 81.31 ± 9.83 | < 0.001 |
Estimated glomerular filtration rate (mL/minute/1.73 m2) | 96.46 ± 37.20 | 96.40 ± 35.24 | 96.20 ± 40.69 | 94.79 ± 43.15 | 0.507 |
Case/total | Model 1 | Model 2 | Model 3 | Model 4 | |||||
HR (95%CI) | P value | HR (95%CI) | P value | HR (95%CI) | P value | HR (95%CI) | P value | ||
Normal was transformed into normal group | 28/1786 | Reference | Reference | Reference | Reference | ||||
Abnormal was transformed into normal group | 18/979 | 1.173 (0.648-2.120) | 0.597 | 1.255 (0.693-2.271) | 0.452 | 1.157 (0.638-2.098) | 0.631 | 1.089 (0.598-1.982) | 0.779 |
Normal was transformed into abnormal group | 34/883 | 2.486 (1.507-4.099) | < 0.001 | 2.692 (1.629-4.449) | < 0.001 | 2.531 (1.526-4.199) | < 0.001 | 2.369 (1.424-3.941) | < 0.001 |
Abnormal was transformed into abnormal group | 63/2446 | 1.654 (1.060-2.582) | 0.026 | 1.827 (1.168-2.859) | 0.008 | 1.584 (1.005-2.497) | 0.015 | 1.448 (1.002-2.298) | 0.047 |
P for trend | 0.156 | 0.168 | 0.182 | 0.233 |
- Citation: Wei CC, Huang YQ, Yu CH. Relationship between longitudinal changes in lipid composition and ischemic stroke among hypertensive patients. World J Clin Cases 2025; 13(4): 95803
- URL: https://www.wjgnet.com/2307-8960/full/v13/i4/95803.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v13.i4.95803